CLAIMS

1. An isolated antibody or antibody derivative that specifically binds to equine interleukine-5 (IL-5) comprising at least one member selected from a group consisting of equine constant light chain, equine constant heavy chain and fragments thereof.

2. The isolated antibody or antibody derivative according to claim 1, wherein the isolated antibody or antibody derivative is a monoclonal isolated antibody or antibody derivative.

3. The isolated antibody or antibody derivative according to claim 1 or 2, wherein the isolated antibody or antibody derivative is aglycosylated.

4. The isolated antibody or antibody derivative according to any one of claims 1 to 3, wherein the isolated antibody or antibody derivative comprises at least one complementary determining region (CDR) amino acid sequence selected from a group consisting of the amino acid sequences as depicted in any one of SEQ ID NOs: 1, 155, 156, 157, 158, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 and 21.

5. The isolated antibody or antibody derivative according to any one of claims 1 to 4, wherein the isolated antibody or antibody derivative comprises a light chain CDR1 amino acid sequence as depicted in SEQ ID NO: 1, a light chain CDR2 amino acid sequence selected from a group consisting of the amino acid sequences as depicted in any one of SEQ ID NOs: 155, 156, 157 and 158, a light chain CDR3 amino acid sequence selected from a group consisting of the amino acid sequences as depicted in any one of SEQ ID NOs: 2, 3, 4 and 5, a heavy chain CDR1 amino acid sequence selected from a group consisting of the amino acid sequences as depicted in any one of SEQ ID NOs: 6, 7, 8 and 9, a heavy chain CDR2 amino acid sequence selected from a group consisting of the amino acid sequences as depicted in any one of SEQ ID NOs: 10, 11, 12, 13 and 14, and a heavy chain CDR3 amino acid sequence selected from a

group consisting of the amino acid sequences as depicted in any one of SEQ ID NOs:15, 16, 17, 18, 19, 20 and 21.

6. The isolated antibody or antibody derivative according to any one of claims 1 to 5 comprising a light chain variable region comprising an amino acid sequence being identical to or having at least 90%, 95%, 98% or 99% sequence homology to an amino acid sequence as depicted in any one of SEQ ID NOs: 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 35, 36 or 37, and/or comprising a heavy chain variable region comprising an amino acid sequence being identical to or having at least 90%, 95%, 98% or 99% sequence homology to an amino acid sequence as depicted in any one of SEQ ID NOs: 38, 39, 40, 41, 42, 43, 45, 49, 50, 51, 52 or 53.

7. The isolated antibody or antibody derivative according to any one of claims 1 to 6 comprising a light chain amino acid sequence being identical to or having at least 90%, 95%, 98% or 99% sequence homology to the amino acid sequence as depicted in SEQ ID NO: 54, and/or comprising a heavy chain amino acid sequence being identical to or having at least 90%, 95%, 98% or 99% sequence homology to the amino acid sequence as depicted in SEQ ID NO: 55 or 153.

8. The isolated antibody or antibody derivative according to any one of claims 1 to 7, wherein the isolated antibody or antibody derivative is an isolated IgG antibody or antibody derivative, preferably, the isolated antibody or antibody derivative is an isolated IgG6 antibody or antibody derivative.

9. The isolated antibody or antibody derivative according to any one of claims 1 to 8, wherein the isolated antibody or antibody derivative has a neutralizing ability towards equine IL-5.

10. An isolated nucleic acid molecule comprising at least one nucleic acid sequence encoding at least partially the isolated antibody or antibody derivative according to any one of claims 1 to 9.

11. A vector comprising at least one nucleic acid sequence encoding at least partially the isolated antibody or antibody derivative according to any one of claims 1 to 9, preferably the vector is an expression vector.

12. A host cell comprising the vector according to claim 11 or at least one nucleic acid sequence encoding at least partially the isolated antibody or antibody derivative according to any one of claims 1 to 9, preferably, the host cell is a eukaryotic host cell.

13. A pharmaceutical composition comprising the isolated antibody or antibody derivative according to any one of claims 1 to 9 and a pharmaceutically acceptable excipient.

14. The isolated antibody or antibody derivative according to any one of claims 1 to 9 or the pharmaceutical composition according to claim 13 for use as a medicament.

15. Use of the isolated antibody or antibody derivative according to any one of claims 1 to 9 or the pharmaceutical composition according to claim 13, in the manufacture of a medicament for the treatment of an allergic condition of a horse.

16. The use according to claim 15, wherein the allergic condition is selected from a group consisting of equine allergic skin disease, equine allergic respiratory disease and inflammatory disease.

17. The use according to claim 16, wherein the equine allergic skin disease is selected from a group consisting of insect-bite hypersensitivity, atopic dermatitis, food hypersensitivity, allergic and irritant contact dermatitis and urticaria, preferably, the equine allergic skin disease is insect-bite hypersensitivity or atopic dermatitis, most preferably, the equine allergic skin disease is insect-bite hypersensitivity.

18. The use according to claim 16, wherein the equine allergic respiratory disease is equine asthma.

19. An *in vitro* method for the diagnosis of an allergic condition in a horse comprising contacting the isolated antibody or antibody derivative according to any one of claims 1 to 9 with a biological sample.

20. A method of manufacturing the isolated antibody or antibody derivative according to any one of claims 1 to 9, comprising expressing the isolated antibody or antibody derivative in a host cell, preferably in a host cell according to claim 12.